Article

LHRH implant for prostate cancer to be discontinued

Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.

Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.

Bayer will fulfill orders until current supplies are depleted, expected by the end of April 2008. Alternative therapies are available for the palliative care of prostate cancer patients. Patients are being advised to discuss these options with their health care providers.

Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
1 KOL is featured in this series.
Related Content
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer
October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke
“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO
"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter
"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
© 2024 MJH Life Sciences

All rights reserved.